Lumiradx Stock Return On Asset
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess LumiraDx's long-term financial health and intrinsic value.
LumiraDx |
LumiraDx Company Return On Asset Analysis
LumiraDx's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current LumiraDx Return On Asset | -0.28 |
Most of LumiraDx's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, LumiraDx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, LumiraDx has a Return On Asset of -0.2804. This is 96.8% lower than that of the Biotechnology sector and 96.28% lower than that of the Health Care industry. The return on asset for all United States stocks is 100.29% higher than that of the company.
LumiraDx Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LumiraDx's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LumiraDx could also be used in its relative valuation, which is a method of valuing LumiraDx by comparing valuation metrics of similar companies.LumiraDx is currently under evaluation in return on asset category among its peers.
LumiraDx Fundamentals
| Return On Equity | -15.64 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (2.67) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 440.16 M | |||
| Shares Outstanding | 161.02 M | |||
| Shares Owned By Insiders | 55.41 % | |||
| Shares Owned By Institutions | 25.26 % | |||
| Number Of Shares Shorted | 1.43 M | |||
| Price To Earning | 13.70 X | |||
| Price To Book | 18.28 X | |||
| Price To Sales | 1.97 X | |||
| Revenue | 254.48 M | |||
| Gross Profit | 61.02 M | |||
| EBITDA | (273.54 M) | |||
| Net Income | (449.19 M) | |||
| Cash And Equivalents | 106.45 M | |||
| Cash Per Share | 0.42 X | |||
| Total Debt | 401.25 M | |||
| Current Ratio | 2.76 X | |||
| Book Value Per Share | (0.67) X | |||
| Cash Flow From Operations | (162.11 M) | |||
| Short Ratio | 0.09 X | |||
| Earnings Per Share | (1.08) X | |||
| Target Price | 0.65 | |||
| Number Of Employees | 1.21 K | |||
| Beta | 1.71 | |||
| Market Capitalization | 249.63 M | |||
| Total Asset | 441.01 M | |||
| Retained Earnings | (1.09 B) | |||
| Working Capital | 179.82 M | |||
| Net Asset | 441.01 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in LumiraDx Stock
If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |